IQVIA adds $2B to share repurchase authorization
IQVIA Holdings Inc. announced that its board of directors approved an additional $2 billion share repurchase authorization under its existing equity repurchase program, bringing the total remaining authorization to $3.2 billion.
Rhea-AI Filing Summary
IQVIA Holdings Inc. announced that its board of directors approved an additional $2 billion share repurchase authorization under its existing equity repurchase program, bringing the total remaining authorization to $3.2 billion. The program has no expiration date and does not require IQVIA to repurchase any specific amount of stock.
Repurchases may be made in open market transactions, block trades, or privately negotiated deals, and can be modified, extended, suspended or discontinued at any time based on IQVIA’s share price, corporate needs and overall market conditions.
Positive
- None.
Negative
- None.
Insights
IQVIA expands its buyback capacity but actual repurchases remain discretionary.
IQVIA increased its remaining share repurchase authorization to $3.2 billion, signaling board support for returning capital through buybacks. The authorization itself is a ceiling, not a commitment, and the company retains full flexibility over timing and volume.
The program has no expiration date and may be modified, suspended or discontinued, so the real impact depends on future management decisions and market conditions. Investors can look to subsequent quarterly disclosures for updates on how much of this authorization is actually utilized.
8-K Event Classification
Key Figures
Key Terms
equity repurchase program financial
block trades financial
Inline XBRL technical
Healthcare grade AI technical
privacy enhancing technologies technical
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Does IQVIA (IQV) have to repurchase a set amount of stock under this program?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
(Address of principal executive offices)
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class |
Trading |
Name of Each Exchange | ||
| “ |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 8.01. | Other Events. |
On May 7, 2026, IQVIA Holdings Inc. (the “Company”) announced that the Company’s board of directors authorized the repurchase of an additional $2,000 million of the Company’s common stock under the Company’s existing equity repurchase program (the “Repurchase Program”), bringing the total remaining authorization to $3,217 million. A copy of the press release is attached and incorporated herein by reference as Exhibit 99.1.
The Repurchase Program does not obligate the Company to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time. The timing and amount of repurchases are determined by the Company’s management based on a variety of factors such as the market price of the Company’s common stock, the Company’s corporate requirements, and overall market conditions. Purchases of the Company’s common stock may be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. The Repurchase Program does not have an expiration date. In addition, from time to time, the Company has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program. The Company may discontinue repurchases without notice at any time.
| Item 9.01. | Financial Statements and Exhibits. |
| Exhibit No. |
Exhibit Description | |
| 99.1 |
Press Release, dated May 7, 2026. | |
| 104 |
Cover Page Interactive Data File (embedded within the Inline XBRL document). | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: May 7, 2026
| IQVIA HOLDINGS INC. | ||
| By: | /s/ Michael J. Fedock | |
| Michael J. Fedock | ||
| Executive Vice President and Chief Financial Officer | ||
Exhibit 99.1
News Release
Contacts:
Kerri Joseph, IQVIA Investor Relations (kerri.joseph@iqvia.com)
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations (alissa.maupin1@iqvia.com)
+1.919.923.6785
IQVIA Board of Directors Approves $2 Billion Increase in Share Repurchase Authorization
RESEARCH TRIANGLE PARK, N.C. – May 7, 2026 – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that its board of directors authorized the repurchase of an additional $2 billion of IQVIA’s common stock under IQVIA’s existing equity repurchase program (the “Repurchase Program”), bringing the total remaining authorization to $3.2 billion.
The Repurchase Program does not obligate IQVIA to repurchase any particular amount of common stock, and it may be modified, extended, suspended or discontinued at any time. The timing and amount of repurchases are determined by IQVIA’s management based on a variety of factors such as the market price of IQVIA’s common stock, IQVIA’s corporate requirements, and overall market conditions. Purchases of IQVIA’s common stock may be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. The Repurchase Program does not have an expiration date. In addition, from time to time, IQVIA has repurchased and may continue to repurchase common stock through private or other transactions outside of the Repurchase Program. IQVIA may discontinue repurchases without notice at any time.
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high quality health data, Healthcare grade AI®, advanced analytics, the latest technologies, and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 93,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology, and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers, and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
IQVIAFIN
# # #